Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: A retrospective analysis of patients treated at a US centre

Drug Safety

Volumn 34, Issue 2, 2011, Pages 117-123

  Brown, Brandon A ^a   Torabi, Mina ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Corticosteroids, general; Histamine H1 receptor antagonists, general; Histamine H2 receptor antagonists, general; Infusion; Monoclonal antibodies, adverse reactions; Multiple sclerosis, treatment; Rituximab, adverse reactions.

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB;

ABNORMAL SENSATION; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EAR PRURITUS; ERYTHEMA; FACE RASH; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION ASSOCIATED REACTION; INFUSION RATE; ITCHY THROAT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; NAUSEA; OCULAR PRURITUS; PAIN; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; THROAT IRRITATION; THROAT TIGHTNESS; TINGLING SENSATION; UNITED STATES; URTICARIA; WEAKNESS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; UNITED STATES;

EID: 78751608752     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11585960-000000000-00000     Document Type: Article

References (25)

1. Rituxan- (rituximab) [package insert]. San Francisco (CA): Biogen Idec Inc. and Genentech, 2009
2. Sailler L. Rituximab off-label use for difficult-to-treat autoimmune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol 2008; 34: 103-10
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-17
4. Lassmann H. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr Opin Neurol 2008; 21: 242-7
5. IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-61
6. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis StudyGroup.Neurology 1995; 45: 1268-76
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
8. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
9. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
10. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23
11. Franciotta D, Salvetti M, Lolli F, et al. B cells in multiple sclerosis. Lancet Neurol 2008; 7: 852-8
12. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 2006; 112: 57-70
13. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88
14. Common terminology criteria for adverse events v3.0 (CTCAE): online instructions and guidelines. Bethesda (MD): National Cancer Institute August 9 2006 [online]. Available from URL: http://ctep.cancer.gov/protocoldevel opment/electronic-applications/docs/ctcaev3.pdf [Accessed 2010 Jan 6].
15. Gaston RS, Zeierhoi MH, Patterson T, et al. OKT3 first dose reaction: association with T cells subset and cytokines release. Kidney Int 1991; 39: 141-7
16. Albrecht H, Radosevich JA, Babich M. Fundamentals of antibody-related therapy and diagnostics. Drugs Today (Barc) 2009; 45: 199-211
17. Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 2008; 14: 2883-91
18. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54 (9): 2793-806
19. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum 2010; 62 (1): 222-33
20. McLaughlin P, Hagemeister FB, Grill-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26 (5 Suppl. 14): 79-87
21. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-71
22. Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400 (Pubitemid 351499869)
23. Schwartzberg LS, Stepanski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 2008; 16: 393-8
24. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-9
25. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 2006; 20 Suppl. 2: 5-13